Comparison of the effects of four antiarrhythmic treatments for familial ventricular arrhythmias in Boxers

Journal of the American Veterinary Medical Association

Volumn 221, Issue 4, 2002, Pages 522-527

  Meurs, Kathryn M ^a   Spier, Alan W ^a   Wright, Nicola A ^a   Atkins, Clarke E ^b   DeFrancesco, Teresa C ^b   Gordon, Sonya G ^c   Hamlin, Robert L ^a   Keene, Bruce W ^b   Miller, Matthew W ^c   Moise, N Sydney ^d  

^a OHIO STATE UNIVERSITY   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

^d Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ATENOLOL; MEXILETINE; PROCAINAMIDE; SOTALOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOG; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; HEART RATE VARIABILITY; HEART VENTRICLE ARRHYTHMIA; NONHUMAN; SYNCOPE; ANIMAL; ANIMAL DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOG DISEASE; DRUG COMBINATION; HEART ARRHYTHMIA; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ATENOLOL; DOG DISEASES; DOGS; DRUG THERAPY, COMBINATION; HEART RATE; MEXILETINE; PROCAINAMIDE; RANDOM ALLOCATION; SOTALOL; SYNCOPE; TREATMENT OUTCOME; VENTRICULAR PREMATURE COMPLEXES;

EID: 0037101892     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.2002.221.522     Document Type: Article

References (29)

1. Familial ventricular arrhythmias in Boxers
2. Boxer cardiomyopathy
3. Long-term oral antiarrhythmic therapy with mexiletine
4. Pharmacology and pharmacokinetics of antiarrhythmic drugs
5. Drugs used in the treatment of cardiac arrhythmias
6. Diagnosis and management of canine arrythmias
7. Echocardiography
8. Determinants of outcome in patients with sustained ventricular tacharrhythmias: The antiarrhythmics versus implantable defibrillators (AVID) study registry
9. Proarrhythmia
10. Drug therapy of sustained ventricular arrhythmias
11. Use of ambulatory electrocardiography for detection of ventricular premature complexes in healthy dogs
12. Spontaneous variability in the frequency of ventricular premature complexes over prolonged intervals and implication for antiarrhythmic treatment
13. Task force of the working group on arrhythmias of the European Society of Cardiology The Sicilian Gambit: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms
14. Beta blockers: Evidence versus wishful thinking
15. Beta blockade, ventricular arrhythmias, and sudden cardiac death
16. Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: The antiarrhythmics versus implantable defibrillators (AVID) trial
17. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias
18. Atenolol, but not mexiletine, protects against stimulus-induced ventricular tachycardia in a chronic canine model
19. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias
20. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs
21. A perspective on the ESVEM trial and current knowledge: Sotalol should not be the first-line agent in the management of ventricular arrhythmias
22. Sotalol: An important new antiarrhythmic
23. Concentration-dependant pharmacologic properties of sotalol
24. Mexiletine administration for management of ventricular arrhythmia in 22 dogs
25. Combined mexiletine and propranolol treatment of refractory ventricular tachycardia
26. Mexiletine (Ko 1173) in the management of ventricular dysrhythmias
27. Beta blockers in combination with class I antiarrhythmic agents
28. The role of beta blocking agents as adjunct therapy to membrane stabilizing drugs in malignant ventricular arrhythmia